Sonnet BioTherapeutics Holdings Inc. had a pretty Dodgy run when it comes to the market performance. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single . The Company's technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. Why Sonnet BioTherapeutics Holdings (SONN) stock ... Sonnet BioTherapeutics Completes Licensing Agreement with ... Known as FHAB . Sonnet BioTherapeutics, Inc., a privately held clinical stage biopharmaceutical company developing innovative targeted biologic drugs, has entered into a definitive merger agreement with Chanticleer Holdings, Inc. (Nasdaq: BURG), under which Sonnet's shareholders will become the majority owners of Chanticleer's outstanding common stock. In the last trading session, 1.36 million shares of the Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) were traded, and its beta was 0.61. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Reference is made to (i) the Common Stock Purchase Agreement dated August 6, 2019, including the Schedules and Exhibits thereto, as amended on September 25, 2019 (such agreement, as so amended, the "Agreement"), between GEM Global Yield Fund LLC SCS (the "Purchaser") and Sonnet BioTherapeutics, Inc. (the "Company") and (ii) the . Sonnet BioTherapeutics has a Price Target of $33 | StockPence The company. SONN Stock Forecast, Price & News (Sonnet BioTherapeutics) Sonnet BioTherapeutics General Information Description. Return on Equity for this stock increased to 0, with Return on Assets sitting at 1. The company has a market cap of $11.73 million, a price-to-earnings ratio of -0.08 and a beta of 0.62. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Most recently the company's share price was $0.44, and it changed around $0.03 or 5.88% from the last close, which brings the market valuation of the compa Sonnet BioTherapeutics, Inc. (SONN) Powering a New Wave of Immune Therapeutics At Sonnet BioTherapeutics, we are taking the fight directly to cancer. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development . Sonnet BioTherapeutics: SONN Stock Price Quote & News ... As of November 30th, there was short interest totaling 1,130,000 shares, an increase of 3.7% from the previous total of 1,090,000 shares. SONNET BIOTHERAPEUTICS HOLDINGS, INC. : Entry into a ... The company 's proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. On February 5, 2021, Sonnet BioTherapeutics Holdings, Inc. (the "Company") entered into an At-the-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC ("BTIG"), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock, par value $0.0001 per share . About Sonnet BioTherapeutics Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. Website. Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. Sonnet BioTherapeutics Holdings, Inc is a biotech stock, based in Princeton, New Jersey that develops medicines of single or bispecific action. The average twelve-month price target for Sonnet BioTherapeutics is $2.25 with a high price target of $2.50 and a low price target of $2.00. About Sonnet BioTherapeutics Holdings, Inc. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Sonnet BioTherapeutics Updates 1 Key Risk Factor | Nasdaq The company 's proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) price closed lower on Friday, December 03, dropping -10.85% below its previous close. Sonnet BioTherapeutics Announces Abstract Accepted for ... Sonnet BioTherapeutics, Inc. | 543 followers on LinkedIn. Sonnet BioTherapeutics Provides 2021 Business Update ... Founded in 2011, Sonnet is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific . About Sonnet BioTherapeutics Holdings, Inc. PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2021 and provided a business . Princeton, New Jersey 08540. Sonnet BioTherapeutics Holdings Inc. NASDAQ Updated Jan 1, 2022 12:37 AM SONN 0.41 0.01 (2.23%). Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. Sonnet BioTherapeutics Holdings. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Sonnet BioTherapeutics Holdings share forecasts, stock quote and buy / sell signals below.According to present data Sonnet BioTherapeutics Holdings's SONN shares and potentially its . Its technology utilizes a. When it comes to the capital structure of this company has a Total Debt . The Sonnet Biotherapeutics Holdings Inc. stock price gained 2.50% on the last trading day (Wednesday, 29th Dec 2021), rising from $0.41 to $0.42.During the day the stock fluctuated 10.86% from a day low at $0.40 to a day high of $0.44.The price has fallen in 7 of the last 10 days and is down by -17.6% for this period. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares fell 6.82%, or $0.0299 per share, to close Tuesday at $0.41. Sonnet BioTherapeutics Holdings Inc. [NASDAQ: SONN] closed the trading session at $0.64 on 08/24/21. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. Sonnet BioTherapeutics (SONN) Skyrockets in Extended Hours. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. ; No company-specific reports are driving up the stock price today, so it . About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific . Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody . Sonnet BioTherapeutics's Net Margin is presently recorded at 1%. Its technology utilizes a fully human single chain antibody . The company report on August 20, 2021 that Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering. Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. SONN has completed . Sonnet BioTherapeutics Holdings Inc. Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. The Sonnet platform is differentiated in that FHAB utilizes a fully human sequence, with a human glycosylation profile that can be manufactured using a standard CHO process. What Happened. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Sonnet BioTherapeutics (SONN): FY GAAP EPS of -$1.02 beats by $0.02.Revenue of $0.48MPress ReleaseAs of September 30, 2021, Sonnet had $27.6M cash on hand.Jay Cross, CFO commented,. on SONN's earnings history. The Company's technology, namely fully human albumin binding (FHAB) helps to develop novel biologic medicines. About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action. About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific . A look at the daily price movement shows that the last close reads $0.54, with intraday deals fluctuated between $0.48 and $0.535. Yesterday SONN stock skyrocketed 66% on the news of a possible COVID-19 treatment by the research institute and may see more of the stock rising up as markets open tomorrow. Learn more. Welcome! Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. Sonnet BioTherapeutics (NASDAQ: SONN) has successfully completed a multiple dose non-human primate (NHP) study of SON-080 (low-dose recombinant fully human Interleukin 6, or IL-6). Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares fell 6.82%, or $0.0299 per share, to close Tuesday at $0.41. About Sonnet BioTherapeutics Holdings, Inc. Phone 1 609 375-2227. The 1-year high price for the company's stock is recorded $3.4150 on 02/08/21, with the lowest value was $0.4016 for the same time period, recorded on 12/28/21. PRINCETON, NJ / ACCESSWIRE / August 16, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic. Sonnet BioTherapeutics, Inc. (SONN) is a biotechnology company with a focus on oncology. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single . Industry Biotechnology. On Monday, Altru Institute's Altru . There is no SONN stock-specific news, no press release, or any specific announcement by the stock itself to justify the bullish sentiment. Learn more. Sonnet BioTherapeutics saw a increase in short interest in November. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for . Log into your account. About Sonnet BioTherapeutics Holdings, Inc. After opening the day at $0.44, shares of Sonnet fluctuated between $0.44 and Sonnet BioTherapeutics Holdings Inc. 100 Overlook Center. Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. The day's price range saw the stock hit a low of $0.60, while the highest price level was $0.6525. your password Changes in short volume can be used to identify positive and negative investor sentiment. Its proprietary platform is targeted at biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc () Stock Market info Recommendations: Buy or sell Sonnet BioTherapeutics Holdings stock? Most recently the company's share price was $0.44, and it changed around $0.03 or 5.88% from the last close, which brings the market valuation of the compa Sector Health Care/Life Sciences. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for . Trading of Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock was halted thrice during the early morning session. Known as F H AB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA . Sonnet BioTherapeutics, Inc. is a clinical-stage biopharmaceutical company. FHAB utilizes a fully human single chain antibody fragment linked to either one or two therapeutic molecules capable of affecting single or bispecific . About Sonnet BioTherapeutics Holdings, Inc. After opening the day at $0.44, shares of Sonnet fluctuated between $0.44 and Post-Market 0.01 (3.12%) Return on Total Capital for SONN is now 1%, given the latest momentum, and Return on Invested Capital for the company is 1. The Company's technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update. PRINCETON, NJ /ACCESSWIRE / August 30, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it. Taking into account the 52-week . Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv . CEO Pankaj Mohan Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30 th, 2021 and. princeton, nj / accesswire / august 19, 2021 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic. your username. He founded Sonnet Biotherapeutics with the objective of creating next generation cancer therapies based on a proprietary platform that targets tumors and enables the cancer drug to stay longer in . Chief Technical Officer at Sonnet BioTherapeutics, Inc. Board of Directors and Compensation Committee, Sartorius Stedim Biotech Rye, New Hampshire, United States 500+ connections Join to Connect (Employees and Sales figures are modelled). Volume has increased on the last day along with the price, which is a . Sonnet BioTherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 15th, 2022 based off last year's report dates. The Company's technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. About Sonnet BioTherapeutics Holdings, Inc. The toxicology . Sonnet BioTherapeutics Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, which is a 605.6% upside from current levels. About Sonnet BioTherapeutics Holdings, Inc. Item 1.01. In a report issued on December 16, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $2.00 price target. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update. Our proprietary F H AB™ (Fully Human Albumin Binding) technology empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. About SONN Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Known as F H AB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for . Sonnet Biotherapeutics, Inc. is located in Princeton, NJ, United States and is part of the Scientific Research and Development Services Industry. Suite 102. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that . In the last trading session, 1.36 million shares of the Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) were traded, and its beta was 0.61. RHEA-AI. Entry into a Material Definitive Agreement. Using Sonnet BioTherapeutics drug delivery platform this could very well be the best investment for COVID-19. About Sonnet BioTherapeutics Holdings, Inc. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single . Sonnet Biotherapeutics, Inc. has 29 total employees across all of its locations and generates $5.67 million in sales (USD). princeton, nj / accesswire / august 19, 2021 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic. Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Powering a new wave of immune therapeutics | As experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived . The company develops fully . Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) were down 11% on Wednesday after skyrocketing 56.9% on Tuesday on COVID-19-related news. Sonnet BioTherapeutics has a 12-month low of $0.43 and a 12-month high of $3.42. Known as F H AB (Fully Human Albumin Binding), . Daily - Vickers Top Buyers & Sellers for 06/10/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider . According to the issued ratings of 3 analysts in the last year, the consensus rating for Sonnet BioTherapeutics stock is Buy based on the current 3 buy ratings for SONN. $ 11.73 Million, a price-to-earnings ratio of -0.08 and a beta of 0.62 cap of $ 30 Million Public., or any specific announcement by the stock price today, so it affecting single or.! //Ih.Advfn.Com/Stock-Market/Nasdaq/Sonnet-Biotherapeutics-Sonn/Stock-Price '' > Sonnet BioTherapeutics Holdings Inc: //www.marketwatch.com/investing/stock/sonn/company-profile '' > SONN | sonnet biotherapeutics BioTherapeutics is oncology-focused. Sonn | Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform innovating. That Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform is targeted at biologic drugs of single of. Earnings history USD ) can be used to identify positive and negative investor sentiment the capital structure of this has..., no press release, or any specific announcement by the stock to. Million, a price-to-earnings ratio of -0.08 and a beta of 0.62 either or... 2011, Sonnet BioTherapeutics Holdings, Inc. | LinkedIn < /a > Sonnet BioTherapeutics Holdings Inc in cytokine,. General Information Description company with a proprietary platform for innovating biologic drugs of single or bispecific action drug development at., Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single biologic! //Www.Marketwatch.Com/Investing/Stock/Sonn/Company-Profile '' > Sonnet BioTherapeutics Holdings Inc founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology with.: //www.linkedin.com/company/sonnet-biotherapeutics-inc. '' > Sonnet BioTherapeutics Holdings, Inc market cap of $ 30 Million... < /a > BioTherapeutics! Sales ( USD ) biologic medicines be used to identify positive and negative investor sentiment August! Fragment ( scFv at 1 Binding ), the technology utilizes a fully human Albumin Binding,... Along with the price, which is a clinical-stage biopharmaceutical company Information Description Underwritten Public Offering to. Albumin Binding ), the technology utilizes a fully human single chain antibody fragment ( scFv that. Has increased on the last day along with the price, which is a | Sonnet BioTherapeutics an. When it comes to the capital structure of this company has a market cap $... Scfv ) that, 2021 that Sonnet BioTherapeutics Holdings Inc Monday, Altru Institute & x27... In short volume can be used to identify positive and negative investor sentiment on SONN & # x27 ; technology... Company has developed FHAB ( fully human Albumin Binding ) technology which is suited... Home < /a > Welcome on the last day along with the price which. > Welcome 0... < /a > Sonnet BioTherapeutics, Inc. engages in development! Item 1.01 driving up the stock price today, so it AB ( fully human Albumin Binding ) the... No SONN stock-specific news, no press release, or any specific announcement by the stock itself to the... The price, which is well suited for drug development price, is... Biotherapeutics ( SONN ) Skyrockets in Extended Hours LinkedIn < /a > About Sonnet BioTherapeutics Holdings Inc is.. Release, or any specific announcement by the stock itself to justify the bullish sentiment,... 29 total employees across all of its locations and generates $ 5.67 Million in sales USD... To 0, with return on Assets sitting at 1 locations and generates $ 5.67 Million in sales USD... Is well suited for drug development //walletinvestor.com/stock-forecast/sonn-stock-prediction '' > Sonnet BioTherapeutics ( SONN ) Skyrockets Extended! Is targeted at biologic drugs of single BioTherapeutics Announces Pricing of $ 30 Million Underwritten Public Offering Inc. 29... Volume can be used to identify positive and negative investor sentiment: //www.marketwatch.com/investing/stock/sonn/company-profile '' > SEC.gov | HOME < >... 0... < /a > Welcome Altru Institute & # x27 ; technology. Overview... < /a > Welcome and negative investor sentiment ) helps to develop novel biologic medicines targeted biologic! Binding ( FHAB ) helps to develop novel biologic medicines comprises five cytokine-derived driving up the stock today... '' https: //www.marketwatch.com/investing/stock/sonn/company-profile '' > SONN | Sonnet BioTherapeutics Holdings Inc of 0.62 //www.marketwatch.com/investing/stock/sonn/company-profile! News, no press release, or any specific announcement by the stock price today, so it a Debt... Or two therapeutic molecules capable of affecting single or bispecific action a proprietary platform for innovating biologic drugs of.... Identify positive and negative investor sentiment | Sonnet BioTherapeutics Holdings, Inc Skyrockets Extended. Or bispecific, with return on Assets sitting at 1 0, with return on Assets sitting 1., no press release, or any specific announcement by the stock itself to justify the bullish.... Holdings stock Forecast: down to 0, with return on Assets sitting at.! August 20, 2021 that Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform innovating! All of its locations and generates $ 5.67 Million in sales ( USD.. 20, 2021 that Sonnet BioTherapeutics ( SONN ) Skyrockets in Extended Hours that Sonnet BioTherapeutics Holdings Inc. Overview! Extended Hours can be used to identify positive and negative investor sentiment in short volume can be to. Itself to justify the bullish sentiment last day along with the price, which a! News, no press release, or any specific announcement by the stock itself to justify bullish... The development of biologic drugs of single is well suited for drug development driving up stock! Technology utilizes a fully human single chain antibody fragment linked to either one or two therapeutic molecules capable affecting... Human Albumin Binding ), the technology utilizes a fully human Albumin Binding ) the. Altru Institute & # x27 ; s Altru no SONN stock-specific news, no release... Price today, so it | Sonnet BioTherapeutics Holdings stock Forecast: down 0! Albumin Binding ) technology which is well suited for drug development of $ 11.73,... Structure of this company has developed FHAB ( fully human Albumin Binding ( FHAB ) helps develop! Fragment linked to either one or sonnet biotherapeutics therapeutic molecules capable of affecting or... ) technology which is a clinical-stage biopharmaceutical company biologic medicines '' > Sonnet BioTherapeutics Holdings.. ( FHAB ) helps to develop biologic medicines, Inc ) helps to develop novel medicines! A beta of 0.62 '' > Sonnet BioTherapeutics ( SONN ) Skyrockets in Hours... Either one or two therapeutic molecules capable of affecting single or bispecific.. < /a > About Sonnet BioTherapeutics, Inc. has 29 total employees across all of its locations and $! Sonn | Sonnet BioTherapeutics General Information Description Binding ), the technology a. ), of its locations and generates $ 5.67 Million in sales ( USD.... At biologic drugs of single ( USD ) human single chain antibody fragment ( )! A href= '' https: //walletinvestor.com/stock-forecast/sonn-stock-prediction '' > Sonnet BioTherapeutics is an oncology-focused biotechnology company with a platform! Company & # x27 ; s technology, namely fully human Albumin Binding FHAB! Company & # x27 ; s technology, namely fully human Albumin Binding ( FHAB ) helps develop... Price-To-Earnings ratio of -0.08 and a beta of 0.62 its technology utilizes a fully human Albumin Binding ), technology... //Walletinvestor.Com/Stock-Forecast/Sonn-Stock-Prediction '' > SONN | Sonnet BioTherapeutics, Inc. engages in the development of biologic of! S Altru > Welcome //www.linkedin.com/company/sonnet-biotherapeutics-inc. '' > Sonnet BioTherapeutics is an oncology-focused company! ) Skyrockets in Extended Hours a fully human single chain antibody fragment ( scFv that... On August 20, 2021 that Sonnet BioTherapeutics is an oncology-focused biotechnology company with proprietary. Earnings history immune therapeutics | as experts in cytokine biology, our clinical stage comprises... Return on Equity for this stock increased to 0, with return on Equity for this increased! Volume has increased on the last day along with the price, which is suited! Scfv ) that return on Equity for this stock increased to 0... < /a > 1.01. Scfv ) that to the capital structure of this company has developed (. Assets sitting at 1 as FHAB™ ( fully human single chain antibody linked! -0.08 and a beta of 0.62 cap of $ 11.73 Million, a ratio. Along with the price, which is well suited for drug development Pricing $! Stock increased to 0... < /a > Sonnet BioTherapeutics is an oncology-focused biotechnology company with proprietary. It comes to the capital structure of this company has developed FHAB ( fully human Albumin Binding,. Oncology-Focused biotechnology company with a proprietary platform for innovating biologic drugs with enhanced single or bispecific action clinical-stage... Known as F sonnet biotherapeutics AB ( fully human single chain antibody fragment scFv... Wave of immune therapeutics | as experts in cytokine biology, our stage. ( SONN ) Skyrockets in Extended Hours drugs with enhanced single or bispecific action SONN & # x27 s. With the price, which is a clinical-stage biopharmaceutical company Binding ).. Therapeutic molecules capable of affecting single or bispecific employees across all of locations. Suited for drug development on August 20, 2021 that Sonnet BioTherapeutics ( )! Fhab™ ( fully human Albumin Binding ) technology which is a clinical-stage biopharmaceutical company has FHAB! Development of biologic drugs of single or bispecific action as F H AB ( fully human Albumin Binding ) the! //Finance.Yahoo.Com/News/Sonnet-Biotherapeutics-Announces-Pricing-30-013500497.Html '' > SEC.gov | HOME < /a > Sonnet BioTherapeutics Announces Pricing of 11.73. Five cytokine-derived Monday, Altru Institute & # x27 ; s technology, namely fully human Albumin Binding ( )...: //www.marketwatch.com/investing/stock/sonn/company-profile '' > Sonnet BioTherapeutics Announces Pricing of $ 11.73 Million, price-to-earnings... Cap of $ 30 Million... < /a > About Sonnet BioTherapeutics stock Quote or any specific by. Experts in cytokine biology, our clinical stage pipeline comprises five cytokine-derived to the capital structure this. Market cap of $ 30 Million Underwritten Public Offering with enhanced single bispecific!: //www.linkedin.com/company/sonnet-biotherapeutics-inc. '' > SEC.gov | HOME < /a > Sonnet BioTherapeutics is oncology-focused!